Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01183598 · ClinicalTrials.gov registry record · Phase 1
A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment
A Phase 1 study of Castleman's Disease, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
- 1
- Study location
NCT01183598: Completed Phase 1 study of Castleman's Disease, sponsored by Hoffmann-La Roche.
NCT01183598 is a Phase 1 study of Castleman's Disease that has completed, run by Hoffmann-La Roche. The registered enrollment target is 3 participants, below the 1,093-participant average among 3 other Castleman's Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01183598, a Phase 1 study of Castleman's Disease, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
- 1
- Study location
Study Summary
This open-label, single center study will provide RoActemra/Actemra (tocilizumab) to a maximum of 4 patients with Multicentric Castelman's Disease who have demonstrated benefit from RoActemra/Actemra in study MRA004US (Chugai Pharma USA) without major toxicities or significant adverse events. Patients will receive their most effective maintenance dose until disease progression or significant toxicity occurs.
Conditions Studied
Interventions
- DRUG tocilizumab [RoActemra/Actemra]
Study Locations (1)
Arkansas
- - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2006-08 |
| Est. Completion | 2011-11 |
| Phase | Phase 1 |
What the finished NCT01183598 record still lists
NCT01183598 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 1,093-participant average among 3 other Castleman's Disease trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Castleman's Disease appearing as the primary indexed condition, and to 1 intervention - of which tocilizumab [RoActemra/Actemra] is the first listed.
NCT01183598 reports a single indexed study location in Arkansas.
Frequently Asked Questions
What is clinical trial NCT01183598 about?
NCT01183598 is a clinical study titled "A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment". This open-label, single center study will provide RoActemra/Actemra (tocilizumab) to a maximum of 4 patients with Multicentric Castelman's Disease who have demonstrated benefit from RoActemra/Actemra in study MRA004US (Chugai Pharma USA) without major toxicities or significant adverse events. Patien...
What is the current status of trial NCT01183598?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2006-08. Estimated completion is 2011-11.
What conditions does trial NCT01183598 study?
This clinical trial studies the following conditions: Castleman's Disease.
What interventions are being tested in trial NCT01183598?
The interventions under investigation include: tocilizumab [RoActemra/Actemra] (DRUG).
Who is sponsoring clinical trial NCT01183598?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01183598 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Castleman's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia